SCF-engineered powders for delivery of budesonide from passive DPI devices

Journal of Pharmaceutical Sciences

Volumn 94, Issue 10, 2005, Pages 2276-2288

  Lobo, Jennifer M ^a   Schiavone, Helena ^a   Palakodaty, Srinivas ^a   York, Peter ^a   Clark, Andy ^a   Tzannis, Stelios T ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Budesonide; Dry powder inhalers; Particle engineering; Pulmonary delivery; Supercritical fluids

Indexed keywords

BUDESONIDE; CHLOROFLUOROCARBON; PROPELLANT;

AEROSOL; ARTICLE; ASTHMA; BIOMEDICAL ENGINEERING; DEVICE; DRUG DELIVERY SYSTEM; DRY POWDER; METERED DOSE INHALER; PARTICLE SIZE; POWDER INHALER; REPRODUCIBILITY; SOLUTION ENHANCED DISPERSION BY SUPERCRITICAL FLUID; SUPERCRITICAL FLUID;

EID: 27944492266     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20305     Document Type: Article

References (33)

1. Wetterlin K. 1988. Turbohaler, a new powder inhaler for administration of drug to the airways. Pharm Res 5:506-508.
2. Crowder TM, Louey MD, Sethuraman W, Smyth HDC, Hickey AJ. 2001. An odyssey in inhaler formulation and design. Pharm Technol 25:99-113.
3. Ashurst I, Malton A, Prime D, Sumby B. 2000. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 3:246-256.
4. Clark AR. 1995. Medical aerosol inhalers: Past, present and future. Aerosol Sci Tech 22:374-391.
5. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. 1994. Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects. Eur Respir J 7:69-73.
6. DeBoer AH, Gjaltema D, Hagedoorn P. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: Effect of peak flow rate (PIFR) and inspiration time on in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 138:45-56.
7. Austin LG, Trass O. 1997. Size reduction of solids: crushing and grinding equipment In: Fayed ME, Otten L, editors. Handbook of powder science and technology. New York: Chapman & Hall, pp. 586-634.
8. Buckton G, Choularton A, Beezer AE, Chatham SM. 1988. The effect of comminution technique on the surface energy of a powder. Int J Pharm 119:25-36.
9. Ward GH, Schultz RK. 1995. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm Res 12:773-779.
10. Gallagher-Wetmore P, Coffey MP, Krukonis V. 1994. Applications of supercritical fluids in recrystallization: Nucleation and gas antisolvent (GAS) techniques. Resp Drug Del 4:287-295.
11. Staniforth JN. 1995. Performance-modifying influences in dry powder inhalers. Aer Sci Technol 22:346-353.
12. Tom JW, Debenedetti PG. 1991. Particle formation in supercritical fluids-A review. J Aerosol Sci 22:555-564.
13. Jung J, Perrut M. 2001. Particle design using supercritical fluids: Literature and patent survey. J Supercritical Fluids 20:179-219.
14. Hanna M, York P. 1994. Method and apparatus for the formation of particles. Patent No. PCT/GB94/ 01426.
15. Meakin BJ, Woodcock PM, Segu A, Niccolai F, Vecchio C. 1996. Evaluation of the resistance to airflow through Turbospin in comparison with dry powder inhalers available on the market. Boll Chim Farmaceutico-Anno 135:107-109.
16. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers LG. 2002. Improved drug delivery from a passive dry powder inhaler using an engineered Pulmosphere® powder. Pharm Res 19:689-695.
17. Srichana T, Martin GP, Marriott C. 1998. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 7:73-80.
18. Tong HHY, Shekunov BY, York P, Chow AHL. 2002. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 19:640-648.
19. Van Oort MM, Dawney B, Roberts W. 1996. Verification of operating the Andersen cascade impactor at different flow rates. Pharm Forum 22:2211-2215.
20. Clark AR, Hollingsworth AM. 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-Implications for in vitro testing. J Aerosol Med 6:99-110.
21. Dunbar CA, Hickey AJ, Holzner P. 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona 16:7-45.
22. Rasenack N, Steckel H, Müller BW. 2003. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci 98:35-44.
23. Steckel H, Thies J, Müller BW. 1997. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm 152:99-110.
24. Jaegfeldt H, Anderson JAR, Trofast E, Wetterlin KIL. 1987. Particle size distribution from different modifications of Turbohaler. In: Newman SP, Morén F, Crompton GK, editors. A new concept in inhalation therapy, London: Medicom, pp. 90-99.
25. Pitcairn GR, Lim J, Hollingsworth A, Newman AP. 1997. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. J Aerosol Sci 10:295-306.
26. Vidgren M, Silvasti M, Vidgren P, Sormunen H, Laurikainen K, Korhonen P. 1995. Easyhaler multiple dose powder inhaler-Practical and effective alternative to the pressurized MDI. Aerosol Sci Technol 22:335-345.
27. Newman SP, Hollingsworth A, Clark AR. 1994. Effect of different modes of delivery from a dry powder inhaler. Int J Pharm 102:127-132.
28. Yeh HC, Phalen RF, Raabe OG. 1976. Factors influencing the deposition of inhaled particles. Environ Health Perspect 15:147-156.
29. Feeley JC. 2002. Powder characterization tests: Can they make a difference in product development? Resp Drug Del 8:295-301.
30. Schiavone H, Palakodaty S, Clark A, York P, Tzannis ST. 2004. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 281:55-66.
31. Feeley JC, York P, Sumby BS, Dicks H. 1998. Determination of surface properties and flow characteristics of salbutamol sulfate before and after micronization. Int J Pharm 172:89-96.
32. Rehman M, Shekunov BY, York P, Miller D, Lechuga-Ballesteros D, Colthorpe P. 2002. Physical characterisation of dry powder aerosols generated by supercritical fluid processing. American Association of Pharmaceutical Scientists Annual Meeting, Toronto, Canada.
33. York P, Hanna M, Shekunov BY, Humphreys GO. 1998. Microfine particle formation by SEDS (Solution Enhanced Dispersion by Supercritical Fluids): Scale up by design. Respiratory Drug Delivery VI Conference Proceedings. USA: Interpharm Press, Inc., pp. 169-175.